In contrast, the EGFR/HER2 small-molecule inhibitor lapatinib showed only limited efficacy in treating advanced gastric cancer (Hecht et al. 2016; Lorenzen et al. 2015; Satoh et al. 2014). The gene discussed is ERBB2; the disease is gastric cancer.